# Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis

> **NCT01912716** · PHASE2,PHASE3 · COMPLETED · sponsor: **Indiana University** · enrollment: 1037 (actual)

## Conditions studied

- Post-ERCP Pancreatitis

## Interventions

- **DRUG:** high dose indomethacin
- **DRUG:** standard dose indomethacin

## Key facts

- **NCT ID:** NCT01912716
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2018-04
- **Final completion:** 2018-10
- **Target enrollment:** 1037 (ACTUAL)
- **Last updated:** 2019-07-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01912716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01912716, "Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01912716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*